Hopes rise for a bright future for paediatric SPC extensions in the EU
This article was originally published in SRA
Executive Summary
It will be good news for the innovative pharmaceutical industry if the Court of Justice of the EU accepts the opinion of one of its advocates general that negative term supplementary protection certificates should be accepted in order to meet the objectives of the regulations governing SPCs and their extension. Mike Snodin reports.